Assembly Biosciences, Inc. (ASMB) stock
ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.50+1.21 (+5.68%)
Close on Nov 17, 2026Market cap $458.11MP/E –Yield –
Assembly Biosciences cash
Cash and short-term investments held at the end of each period.
Assembly Biosciences's cash was $320.40M at Jun 30, 2026. For fiscal 2025 it was $248.10M, up 121.4% from the year before. Over ten years it grew 13.9% a year on average. The highest annual figure on record is $274.04M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $248.10M | +121.4% |
| FY2024 | Dec 31, 2024 | $112.08M | -13.9% |
| FY2023 | Dec 31, 2023 | $130.25M | +42.2% |
| FY2022 | Dec 31, 2022 | $91.61M | -37.5% |
| FY2021 | Dec 31, 2021 | $146.63M | -32.2% |
| FY2020 | Dec 31, 2020 | $216.41M | -21.0% |
| FY2019 | Dec 31, 2019 | $274.04M | +25.7% |
| FY2018 | Dec 31, 2018 | $218.08M | +81.8% |
| FY2017 | Dec 31, 2017 | $119.95M | +126.5% |
| FY2016 | Dec 31, 2016 | $52.96M | -21.7% |
| FY2015 | Dec 31, 2015 | $67.66M | +132.6% |
| FY2014 | Dec 31, 2014 | $29.09M | +7.5% |
| FY2013 | Dec 31, 2013 | $27.06M | +32.1% |
| FY2012 | Dec 31, 2012 | $20.49M | -44.6% |
| FY2011 | Dec 31, 2011 | $36.98M | +153.8% |
| FY2010 | Dec 31, 2010 | $14.57M | +17825.2% |
| FY2009 | Dec 31, 2009 | $81.29K | +412.8% |
| FY2008 | Dec 31, 2008 | $15.85K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $320.40M | +327.2% |
| Q1 FY2026 | Mar 31, 2026 | $226.60M | +148.9% |
| Q4 FY2025 | Dec 31, 2025 | $248.10M | +121.4% |
| Q3 FY2025 | Sep 30, 2025 | $232.60M | +145.0% |
| Q2 FY2025 | Jun 30, 2025 | $75.00M | -31.3% |
| Q1 FY2025 | Mar 31, 2025 | $91.03M | -19.4% |
| Q4 FY2024 | Dec 31, 2024 | $112.08M | -13.9% |
| Q3 FY2024 | Sep 30, 2024 | $94.95M | +105.5% |
| Q2 FY2024 | Jun 30, 2024 | $109.22M | +82.5% |
| Q1 FY2024 | Mar 31, 2024 | $112.98M | +54.7% |
| Q4 FY2023 | Dec 31, 2023 | $130.25M | +42.2% |
| Q3 FY2023 | Sep 30, 2023 | $46.21M | -57.5% |
| Q2 FY2023 | Jun 30, 2023 | $59.83M | -48.7% |
| Q1 FY2023 | Mar 31, 2023 | $73.02M | -40.6% |
| Q4 FY2022 | Dec 31, 2022 | $91.61M | -37.5% |
| Q3 FY2022 | Sep 30, 2022 | $108.65M | -39.9% |
| Q2 FY2022 | Jun 30, 2022 | $116.69M | -41.4% |
| Q1 FY2022 | Mar 31, 2022 | $123.00M | -42.8% |
| Q4 FY2021 | Dec 31, 2021 | $146.63M | -32.2% |
| Q3 FY2021 | Sep 30, 2021 | $180.90M | -24.0% |
| Q2 FY2021 | Jun 30, 2021 | $199.08M | -12.2% |
| Q1 FY2021 | Mar 31, 2021 | $214.88M | -13.7% |
| Q4 FY2020 | Dec 31, 2020 | $216.41M | -21.0% |
| Q3 FY2020 | Sep 30, 2020 | $237.94M | +51.6% |
| Q2 FY2020 | Jun 30, 2020 | $226.71M | +30.4% |
| Q1 FY2020 | Mar 31, 2020 | $249.13M | +28.7% |
| Q4 FY2019 | Dec 31, 2019 | $274.04M | +25.7% |
| Q3 FY2019 | Sep 30, 2019 | $156.94M | -32.9% |
| Q2 FY2019 | Jun 30, 2019 | $173.81M | +87.6% |
| Q1 FY2019 | Mar 31, 2019 | $193.54M | +77.3% |
| Q4 FY2018 | Dec 31, 2018 | $218.08M | +81.8% |
| Q3 FY2018 | Sep 30, 2018 | $233.94M | +252.9% |
| Q2 FY2018 | Jun 30, 2018 | $92.67M | +22.6% |
| Q1 FY2018 | Mar 31, 2018 | $109.16M | +20.1% |
| Q4 FY2017 | Dec 31, 2017 | $119.95M | +126.5% |
| Q3 FY2017 | Sep 30, 2017 | $66.30M | +13.1% |
| Q2 FY2017 | Jun 30, 2017 | $75.58M | – |
| Q1 FY2017 | Mar 31, 2017 | $90.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $52.96M | – |
| Q3 FY2016 | Sep 30, 2016 | $58.65M | – |
See a number that looks wrong?